FRM
CRSP icon

Fox Run Management’s CRISPR Therapeutics CRSP Stock Holding History

Fox Run Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$572K Buy
+10,490
New +$553K 0.09% 421
2025
Q2 		– Sell
-18,473
Closed -$629K – 934
2025
Q1 		$629K Buy
+18,473
New +$783K 0.1% 391
2023
Q4 		– Sell
-4,511
Closed -$205K – 771
2023
Q3 		$205K Sell
4,511
-2,325
-34% -$120K 0.06% 557
2023
Q2 		$384K Buy
+6,836
New +$388K 0.11% 360
2020
Q1 		– Sell
-5,334
Closed -$325K – 169
2019
Q4 		$325K Buy
+5,334
New +$291K 0.26% 157
2018
Q3 		– Sell
-11,347
Closed -$667K – 618
2018
Q2 		$667K Buy
+11,347
New +$646K 0.21% 150

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fox Run Management's CRSP Position: Q2 2026 in Review

Fox Run Management opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 10,490 shares worth $572K. The stake represents 0.09% of the portfolio and ranks #421 among its holdings. This is a return to the name: Fox Run Management previously reported a position in CRSP as recently as Q1 2025.

Fox Run Management first reported a position in CRSP in Q2 2018 and has held it in 6 quarters since. The position peaked at $667K in Q2 2018. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Fox Run Management held 10,490 shares of CRISPR Therapeutics worth $572K as of Q2 2026.
  • CRISPR Therapeutics was a new Fox Run Management position in Q2 2026.
  • CRISPR Therapeutics made up 0.09% of Fox Run Management's portfolio in Q2 2026, its #421 holding.
  • Fox Run Management first reported a position in CRISPR Therapeutics in Q2 2018 and has held it in 6 quarters since.
  • Fox Run Management's CRISPR Therapeutics position peaked at $667K in Q2 2018.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.